Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.
By Peter M. Rothwell, Jacqueline F. Price, Gerald R Fowkes, A. Zanchetti, M. Roncaglioni, G. Tognoni, Robert J Lee, Jill Belch, Michelle Wilson, Z. Mehta and 1 more. The Lancet, 2012
799 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/ff410dc9c214d07d9a88a9279fa32a443f719ba5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pharmacology
Citations in the corpus
- ESH / ESC Guidelines for the management of arterial hypertension (2013, result): “It is noteworthy that a recent meta-analysis has shown lower incidences of cancer and mortality in the aspirin (but not the warfarin) arm of primary prevention trials.(659) If confirmed, this additional action of aspirin may lead to a more liberal reconsideration of its use.”
- 2013 ESH/ESC Guidelines for the management of arterial hypertension (2007, result): “It is noteworthy that a recent meta-analysis has shown lower incidences of cancer and mortality in the aspirin (but not the warfarin) arm of primary prevention trials.(659) If confirmed, this additional action of aspirin may lead to a more liberal reconsideration of its use.”